Vapotherm is set to debut its Access365 home ventilator to enhance the quality of life for patients with late-stage hypercapnic chronic obstructive pulmonary disease (COPD).
The device helps in reducing hospital readmissions and healthcare equipment (HME) costs.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It integrates various advanced features, including ventilation-assured pressure support (VAPS) and volume control/assist ventilation modes, alongside Vapotherm’s established high-velocity therapy.
A medical-grade humidifier is built into the device, which also has integrated Bluetooth-enabled pulse oximetry and spirometry.
Furthermore, the Access365 Home Ventilation Solution offers cloud connectivity, facilitating remote data access and system updates.
It also features a patient engagement platform designed to interrupt the cycle of symptom exacerbation and hospital readmission by enabling the early detection of deteriorating symptoms, thus allowing for quick clinical responses.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataVapotherm chief medical officer Dr Jessica Whittle said: “Our mission is to improve quality of life and reduce hospital readmissions for patients who struggle with respiratory disease.
“Access365 will provide optimal treatment at home, especially for COPD patients, by combining the known benefits of nocturnal NIV [non-invasive ventilation] with the comfort of high-velocity therapy for daytime use.”
Vapotherm anticipates that the home ventilator will receive clearance from the US Food and Drug Administration in early 2025.
Vapotherm president and CEO Joe Army said: “Vapotherm is committed to supporting patients both in and out of the hospital. The recently announced discontinuation of Philips Respironics home ventilators in the US highlights a potential concern for patients and HMEs alike but also a unique opportunity for Vapotherm.
“We are excited to be able to provide newer and more comprehensive options for these patients and the HMEs that support them.”
The device is planned to be unveiled at the MEDTRADE conference in Dallas, US, on 27 March 2024.
Last month, Vapotherm received regulatory approval for its high-velocity therapy (HVT) 2.0 system in Brazil.
